Scarica l'app Stockscreener
1.02
1.92%
-0.02
Dopo l'orario di chiusura:
1.04
0.02
+1.96%
Precedente Chiudi:
$1.04
Aprire:
$1.06
Volume 24 ore:
364.96K
Relative Volume:
0.33
Capitalizzazione di mercato:
$96.17M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-3.8563
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-10.53%
1M Prestazione:
+31.95%
6M Prestazione:
+39.92%
1 anno Prestazione:
-1.92%
Intervallo 1D:
$1.00
$1.07
Intervallo di 1 settimana:
$1.00
$1.14
Portata 52W:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.02 | 100.47M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
(ONC) Financial Trading Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - BioSpace
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - PR Newswire
What’s the recovery path for long term holders of Oncolytics Biotech Inc.High Conviction Intraday Stock Signals Detected - metal.it
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks - Baystreet.ca
Oncolytics Biotech to engage FDA on potential pancreatic cancer study - Investing.com Australia
Bollinger Bands Expand on Oncolytics Biotech Inc. — Volatility AheadRisk Controlled Picks With Real Returns Outlined - metal.it
Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial | 2025-07-29 | Investing News - Stockhouse
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study - TipRanks
Published on: 2025-07-29 15:02:09 - metal.it
Oncolytics Biotech's Strategic FDA Engagement: A Catalyst for Market Redefinition in Pancreatic Cancer - AInvest
What makes Oncolytics Biotech Inc. stock price move sharplyAI Forecast for Trending Stocks Indicates Upside - metal.it
What are the latest earnings results for Oncolytics Biotech Inc.Maximize returns with smart investment plans - jammulinksnews.com
What catalysts could drive Oncolytics Biotech Inc. stock higher in 2025Discover hidden gems in the stock market - jammulinksnews.com
What institutional investors are buying Oncolytics Biotech Inc. stockInvest confidently with professional market insights - jammulinksnews.com
How Oncolytics Biotech Inc. stock performs during market volatilityGrowth Stock Monitor - metal.it
Why is Oncolytics Biotech Inc. stock attracting strong analyst attentionReal-time trading signals for maximum returns - jammulinksnews.com
What is the dividend policy of Oncolytics Biotech Inc. stockGet real-time updates on market trends - jammulinksnews.com
How many analysts rate Oncolytics Biotech Inc. as a “Buy”Build a portfolio that outperforms consistently - jammulinksnews.com
Is it the right time to buy Oncolytics Biotech Inc. stockBuild a portfolio that outperforms consistently - jammulinksnews.com
H.C. Wainwright Analyst Reiterates Buy Rating on Oncolytics Biotech with $5 Price Target - AInvest
Buy Rating for Oncolytics Biotech Driven by Promising Pelareorep Data in Pancreatic and Colorectal Cancers - TipRanks
What drives Oncolytics Biotech Inc. stock priceSuperior trading gains - PrintWeekIndia
Is Oncolytics Biotech Inc. a good long term investmentRecord-breaking capital gains - PrintWeekIndia
Oncolytics Biotech Inc. Stock Analysis and ForecastConsistently high yield - Autocar Professional
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - Eastern Progress
(ONC) Technical Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
What analysts say about Oncolytics Biotech Inc. stockFree Stock Market Real-Time Monitoring - jammulinksnews.com
Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025 - The Globe and Mail
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event - TipRanks
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential - Barchart.com
Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025 - Baystreet.ca
Pancreas Cancer Becoming Top Focus for Biotech Co.? - streetwisereports.com
Oncolytics Biotech Regains Compliance With Nasdaq's Minimum Bid Price Rule - 富途牛牛
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.43%
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):